Stockreport

Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

Korro Bio, Inc.  (KRRO) 
PDF - Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB [Read more]